Chardan initiated coverage of Praxis Precision (PRAX) with a Buy rating and $80 price target The firm cites the potential of the company’s epilepsy franchise for the Buy rating. Praxis Precision’s lead asset ulixacaltamide recently failed the interim analysis of the Phase 3 essential tremor program, but the focus has now shifted to it epilepsy franchise, which has multiple products entering late-stage studies, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Advancements and Financial Outlook
- Praxis Precision price target raised to $76 from $73 at Baird
- Praxis Precision hosted investor event on clinical programs
- Praxis Precision Medicines Shares Promising EMBOLD Study Data
- Praxis Precision reports Q1 EPS ($3.29), consensus ($3.21)